Supply of products by iNova Pharmaceuticals

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring that they meet safety, quality, and efficacy standards. The Act provides the legal framework for the Therapeutic Goods Administration (TGA) to control the importation, manufacture, and supply of therapeutic goods, including medicines, medical devices, and blood products. The problem this legislation addresses is the need to regulate the quality and safety of therapeutic goods to protect public health. The TGA, as a delegate of the Secretary of the Department of Health, exercises its authority under the Act to provide consent for specific products to be supplied under certain conditions, such as ensuring that they comply with relevant regulations and orders, including labelling and batch numbering requirements. This specific consent given on October 1, 2013, pertains to the supply of phenoxymethylpenicillin products by iNova Pharmaceuticals (Australia) Pty Ltd, subject to conditions aimed at ensuring the products meet necessary labelling standards. The policy objective is to safeguard public health by ensuring that therapeutic goods supplied in Australia are of acceptable quality and safety.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, including medicines, medical devices, blood and tissues, and cosmetics. The Act applies to a wide range of entities and individuals, including manufacturers, importers, suppliers, and health professionals, who are involved in the supply, advertising, or representation of therapeutic goods. The Act also applies to the conduct and transactions related to these goods. The scope of the Act extends across the Commonwealth, encompassing the entire nation, with each state and territory having the ability to enforce its provisions within their jurisdiction. Notably, the Act does not apply to goods that are intended solely for personal use or for use in clinical trials under specific conditions. The Act's application can be further delineated through various Therapeutic Goods Orders and Regulations, which provide detailed rules and standards that must be adhered to by entities and individuals within the regulated industries. These subordinate instruments help to refine and extend the application of the Act, ensuring comprehensive oversight of therapeutic goods in Australia.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") is a pivotal piece of Australian legislation that regulates the supply, quality, and safety of therapeutic goods. Specifically, section 14(1) empowers the Secretary of the Department of Health to give consent for the supply of therapeutic goods that do not fully comply with the Therapeutic Goods Regulations. In this case, section 14A(1) is also relevant as it allows the Secretary to impose conditions on such consent. The specific instance under scrutiny here concerns the supply of phenoxymethylpenicillin (LPV) (as potassium) 250 mg and 500 mg capsule blister packs by iNova Pharmaceuticals (Australia) Pty Ltd, which do not conform to paragraphs 3(2)(h) and (i) of Therapeutic Goods Order (TGO) 69 due to the absence of appropriate prefixes for batch numbers and expiry details. Under this consent, several obligations are placed upon iNova Pharmaceuticals. Firstly, they must ensure that the aforementioned batches—130434, 130435, 130432, 130433, and 130780—are supplied in accordance with the conditions outlined by the Secretary. Moreover, they must include a 'Dear Pharmacist' letter with each batch, advising healthcare practitioners to keep the blister platforms in the correctly labelled cartons. This measure aims to mitigate any risk associated with the non-compliance of the batch numbers and expiry details. Failure to comply with the conditions set forth in the consent, or any other requirements under the Act, can have significant consequences. The Act stipulates that breaches may result in civil or criminal penalties. For civil penalties, section 29 of the Act provides that a person who contravenes the Act can be liable to a penalty not exceeding the greater of three times the benefit obtained from the contravention or $111,000. Criminal penalties are also applicable, with section 30 of the Act outlining that an individual or corporation found guilty of an offence can be fined up to $1,110,000 for an individual offence and $5,550,000 for a corporate offence. These penalties underscore the seriousness with which the Act treats non-compliance and the importance of adhering to the regulatory framework established by the Therapeutic Goods Administration.